Nostos Genomics Pitch Deck Teardown: A Masterclass in High-Science Market Positioning

Nostos Genomics raised $5.6M in 2021 with a deck that masterfully identifies a 'bottleneck' in the genetic testing value chain. While sequencing costs have plummeted, the interpretation of data remains manual and inefficient. The deck uses a clean, five-step process diagram to explain their AION platform, which automates variant interpretation. By framing the problem as a 70% failure rate in current genetic testing diagnoses, the company creates a compelling 'why now' narrative. The team slide is particularly strong, showcasing a mix of deep scientific expertise (150+ papers) and commercial e…

Key takeaways

• The deck identifies a critical bottleneck on Slide 3: while sequencing costs have dropped, only ~30% of patients currently receive a diagnosis when doing a genetic test.
• Slide 5 provides a clear five-step visualization of the AION platform, showing how it moves from a VCF file to a final report with confidence scores.
• Market size is framed through three distinct verticals on Slide 7: Diagnostic & Preventive Testing ($32B by 2027), Health Care Systems (e.g., NHS sequencing 500k genomes), and Pharma ($242B orphan drug market).
• The team slide (Slide 9) emphasizes a 'strong scientific track record' with over 150 published papers and links to top European universities.
• The leadership team includes a mix of MD/PhDs and commercial leaders who helped scale startups like Cera Care from 8 to 2,000 employees (Slide 9).
• The deck highlights a massive cost reduction in sequencing from $3 billion to less than $1,000 in the past 15 years as a primary market driver (Slide 7).
• Slide 11 explicitly states the value proposition: doubling the number of diagnoses to help the 70% of patients who currently remain undiagnosed.
• The deck omits a specific 'Ask' slide detailing the exact use of the $5.6M raised, focusing instead on the long-term mission.

Frequently asked questions

What is the core problem Nostos Genomics is solving?

According to Slide 3, the core problem is that the diagnosis of genetic diseases is still a manual and labor-intensive process. Despite the 'Cambrian explosion' in treatments and the sharp decline in sequencing costs, approximately 70% of patients who undergo genetic testing still fail to receive a definitive diagnosis.

How does the AION platform work according to the deck?

Slide 5 outlines a five-step automated process: 1) User uploads a VCF file and symptoms, 2) Data is processed by a proprietary Classifier and Prioritizer, 3) A list of top 10 variants is presented, 4) The user selects relevant variants, and 5) A final report with confidence scores and CSV export is generated.

What are the primary market drivers identified by the founders?

Slide 7 identifies three drivers: the decline in sequencing costs (now under $1,000), increased government investment (such as the NHS aiming for 500,000 whole genomes sequenced by 2024), and the massive investment by Pharma into gene-related drug development for the $242B orphan drug market.

What is the background of the Nostos Genomics leadership team?

The team (Slide 9) features a blend of academic and commercial expertise. It includes Dr. Rocío Acuña Hidalgo (CTO), an MD/PhD in human genetics; Dr. Ansgar Lange (COO), who helped scale Cera Care to 2,000 employees; and specialists in AI and computational genomics with experience at AstraZeneca and Genomics England.

Does the deck include financial projections or a specific funding ask?

No. The 12-slide deck focuses on the problem, solution, market opportunity, and team. It lacks a detailed financial model, specific revenue projections, or a slide detailing how the $5.6M Seed round will be allocated across hiring, R&D, or sales.

You’ve studied Nostos Genomics’ deck. Now score yours.

Upload your pitch deck and get AI-powered feedback to strengthen your pitch.

• Overall score
• Slide-by-slide feedback
• Prioritized fixes

Get My Pitch Score

Nostos Genomics pitch deck: the facts

Company

Nostos Genomics

Year

2021

Stage

Seed

Slides

12

Sector

Healthcare

Outcome

$5.6M raised

Nostos Genomics pitch deck PDF

The full Nostos Genomics deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Nostos Genomics pitch deck was used for

This deck is Nostos Genomics’ 12‑slide **seed fundraising** presentation used to raise around **€5M (~$5.6M) in 2021/early 2022** for its AI‑driven genetic diagnostics software.[1][2][15] It was aimed at investors in healthcare and software to finance expansion of the company’s AION platform that helps genetic testing labs interpret variants for rare disease diagnosis.[1][3][11] The round’s proceeds were earmarked for expanding into new European markets and the US, growing the development team and headcount, and launching clinical studies validating the technology.[1][2][9] The Business Insider article explicitly links this 12‑slide deck to the €5M/$5.6M seed raise.[1]

Business model: B2B SaaS/clinical decision-support: Nostos Genomics provides an AI-driven genetic analysis platform (AION) to genetic testing labs and healthcare professionals to speed and improve interpretation of genetic variants in rare disease diagnostics.[3][5][7][11]

Round

Seed[1][2][15]

Raised

Approximately €5M (~$5.6M–$5.7M) seed funding.[1][2][15]

Lead investor

42CAP and Frontline Ventures (co-leads)[1][2][15]

Investors

42CAP (co-lead)[1][2][15], Frontline Ventures (co-lead)[1][2][15], Amino Collective[2][11][15], Entrepreneur First[2][11][15], Acequia Capital[2][11][15], Kindred Capital[2][11][15], Individual angels including Konstantin Mehl and Robert Fenton[2][11][15]

Founded

2018[4][7][11][12]

Headquarters

Berlin, Germany[4][5][7][12]

Industry

Healthcare / Bioinformatics / Genetic diagnostics software[3][4][11][12]

Year: 2021–2022 (round closed around late 2021; publicly announced February 2022).[1][2][8][15]

Total funding: Approximately €5M–€5.9M (~$5.6M–$5.9M) seed funding announced February 2022; multiple earlier seed/accelerator rounds are listed but amounts largely undisclosed or redacted in public databases.[1][2][8][14][15]

Use of funds as presented: Expansion into new European markets and the US; growth of the development team and headcount; and initiation of clinical and validation studies for the AION platform.[1][2][9][11]

What happened after the Nostos Genomics deck

After raising approximately €5M (~$5.6M) in a seed round linked to this deck, Nostos Genomics expanded its AI-driven AION platform for variant interpretation and later achieved a strategic exit through acquisition by Limbus (varvis). The company progressed beyond seed stage with growing market presence in rare disease diagnostics before the acquisition.[1][2][7][9][11]

• Emergence from stealth around early 2021, with AION positioned as an AI decision-support solution for variant interpreta
• Completion of a seed round of approximately €5M (~$5.6M–$5.7M) announced in February 2022, co-led by 42CAP and Frontline
• Expansion plans into additional European markets and the United States, alongside growth of the development team and ini
• Subsequent acquisition of Nostos Genomics GmbH by Limbus (varvis), integrating AION into a broader rare disease diagnost

What the Nostos Genomics deck got right

• Compelling, well-defined problem in rare disease diagnostics. Nostos Genomics addresses a **clear, high-stakes bottleneck** in genetic disease diagnostics—variant interpretation—making the problem and its impact on patients and healthcare workflows easy for investors to grasp despite the underlying scientific complexity.[1][3][11]
• Differentiated technology stack (AI + synthetic biology). The company’s platform combines **machine learning with synthetic biology-derived functional data**, a differentiated technological approach that promises to characterize mutations at scale and automate interpretation beyond conventional in silico tools.[3][5][9][11]
• Demonstrated ability to secure substantial seed capital. The deck is tied to a relatively **large seed round (€5M/~$5.6M)** for a bioinformatics startup, signaling investor confidence and enabling meaningful expansion and validation activities rather than just incremental R&D.[1][2][15]
• Strong investor syndicate with software and healthcare focus. The seed round attracted **specialist software and early-stage investors**, including 42CAP and Frontline Ventures as co-leads and several experienced angels, which validates the platform’s potential as a scalable B2B SaaS decision-support product.[1][2][11][15]
• Clear roadmap for deploying capital toward growth and validation. Public statements about using funds to expand into new markets, grow the team, and run studies demonstrate a **clear, execution-oriented use-of-proceeds plan** that connects the raise to concrete milestones in commercialization and validation.[1][2][9][11]
• Evidence of strategic value creation leading to acquisition. Subsequent acquisition by Limbus (varvis) indicates the company and its AION platform were able to create **strategic value for a larger player**, suggesting that the business case articulated in the deck translated into a viable product and market presence.[7]

What could have been stronger

• Limited explicit regulatory detail. External descriptions emphasize Nostos Genomics as an AI‑driven decision-support platform but there is little evidence that the deck itself quantifies **regulatory status** (e.g., CE-IVD, FDA, quality management) beyond high-level claims; this would concern investors in clinical diagnostics given the need for regulatory clarity.[3][5][11]
• Sparse quantified traction and adoption data. Sources highlight the platform’s promise but provide few publicly visible **hard metrics** (number of labs onboarded, tests processed, diagnostic uplift, revenue). If the deck similarly focused on qualitative bottlenecks without robust traction data, investors may see this as a weakness in demonstrating product-market fit.[1][2][11]
• Complex prior funding story with limited transparency. GenomeWeb’s 2021 coverage mentions prior VC backing from Entrepreneur First, Amino Collective and Acequia Capital but notes undisclosed investment amounts, implying a somewhat complex financing history.[11] If the deck did not clearly map earlier rounds, this could make cap table and runway less transparent to new seed investors.
• Underdeveloped commercialization and reimbursement narrative. While the company aims to expand in Europe and the US, public materials focus more on the technology than on **go-to-market strategy** (pricing model, sales cycle, reimbursement considerations). A deck that mirrors this imbalance may underdevelop its commercialization narrative versus its technical strengths.[3][11]

How an investor would read this deck

What draws attention

• Strength and uniqueness of Nostos’ AI‑driven variant interpretation technology and synthetic biology data generation, including differentiation from existing clinical decision-support tools.[3][5][9][11]
• Evidence that AION materially reduces time to diagnosis and improves diagnostic yield (uplift in solved cases, speed gains, cost savings) compared with current workflows.[1][3][9][11]
• Regulatory and clinical validation status (CE-IVD, clinical studies, publications) and how that supports adoption by hospital and reference labs.[3][5][11]
• Scalability of the platform’s data infrastructure and machine learning models to handle growing volumes of genomic data across multiple labs and geographies.[3][4][11]
• Market expansion plan into Europe and the US, including sales motion, partnerships with labs, and path to reimbursement/coverage for decision-support tools.[1][2][9][11]

Risks that stand out

• Regulatory and clinical risk: insufficient or slow-to-develop regulatory approvals and rigorous clinical validation could hinder adoption in hospital and reference labs.[3][11]
• Execution risk in commercialization: transitioning from a highly technical product to a scalable sales and customer success machine across Europe and the US may be challenging.[1][2][11]
• Competitive risk: multiple established players and emerging startups address variant interpretation; without strong differentiation and entrenched relationships, Nostos could face pricing pressure and slower growth.[3][4][11]
• Data and privacy risk: handling sensitive genomic and patient data across jurisdictions introduces security and compliance requirements that could lead to operational or legal issues if not managed robustly.[3][11]
• Dependence on continuous performance of machine learning models and synthetic biology pipelines; if models drift or data quality degrades, clinical outcomes and customer trust could be impacted.[3][5][9][11]

Questions this deck invites

• What concrete clinical validation (prospective and retrospective studies, publications) demonstrates that AION improves diagnostic speed and accuracy versus current standard-of-care variant interpretation workflows?[1][2][9][11]
• Which regulatory approvals or certifications (e.g., CE-IVD, ISO, local data protection compliance) did the platform have at the time of the seed round, and how do these support clinical deployment in Europe and the US?[3][5][11]
• What were Nostos Genomics’ key traction metrics at the time of this deck (number of customer labs, samples processed, revenue, retention, and pipeline) and how did those compare to internal targets?[1][2][11]
• How is the pricing structured (per-sample, per-seat SaaS, enterprise license), and what does the typical sales cycle and implementation timeline look like for a new lab customer?[3][11]
• How crowded is the competitive landscape in variant interpretation software, and what are the specific technological or data advantages that allow Nostos to win and retain accounts long term?[3][4][11]

What founders can take from the Nostos Genomics deck

• Anchoring a pitch in a **specific bottleneck**—in this case variant interpretation in genetic diagnostics—helps investors quickly see how complex genomics technology translates into a clear, venture-scale opportunity.[1][11]
• Connecting advanced technology (AI and synthetic biology) directly to **patient impact metrics** like speed and clarity of diagnosis makes a healthcare software story more compelling to generalist and software-focused investors.[1][3][9][11]
• Demonstrating a plan to **expand geographically** (into key European markets and the US) and to grow the development team signals how seed capital will convert into scale, rather than just more research.[1][2][9]
• Highlighting **software-focused lead investors** (such as 42CAP and Frontline Ventures) can reinforce that a genomics company is building a scalable platform business, not only a research project.[1][2][15]
• For clinically oriented startups, showing that the product is already **embedded in real-world workflows** at genetic testing labs and backed by early clinical studies can reduce perceived risk and justify a sizable seed round.[3][9][11]
• Maintaining continuity between the story in the pitch deck and later public communications (company site, press coverage) strengthens credibility and shows that the startup has executed broadly along the trajectory it originally pitched.[1][2][3][11]

Nostos Genomics pitch deck: common questions

What does Nostos Genomics do?

Nostos Genomics is a Berlin-based bioinformatics startup that develops **AION**, an AI-driven decision-support platform used by genetic testing labs to interpret genetic variants and provide faster, more accurate diagnoses for rare genetic diseases.[3][4][7][11]

How much did Nostos Genomics raise with this pitch deck and when?

According to Business Insider and multiple funding trackers, Nostos Genomics raised approximately **€5M (~$5.6M) in a seed round announced in early 2022**, using a 12-slide pitch deck that framed the company’s technology as solving bottlenecks in genetic disease diagnostics.[1][2][14][15]

Who invested in Nostos Genomics’ seed round associated with this deck?

GenomeWeb and CB Insights report that the **seed round was co-led by software investors 42CAP and Frontline Ventures**, with participation from Amino Collective, Entrepreneur First, Acequia Capital, Kindred Capital and several angels including Konstantin Mehl and Robert Fenton.[2][11][15]

What was the funding from this seed round used for?

Public sources describe the funds being used to **expand to new European markets and the US**, grow the development and commercial teams, and **launch validation studies** demonstrating AION’s ability to streamline variant interpretation and improve diagnostic speed.[1][2][9][11]

What happened to Nostos Genomics after this seed round?

Later information indicates Nostos Genomics was **acquired by Limbus (varvis)**, with its AION platform integrated into a broader rare disease diagnostics offering, showing that the company progressed beyond the seed stage and found a strategic exit.[7]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• Nostos Genomics Raised $5.6m Using 12-Slide This Pitch Deck
• Nostos Genomics Raises €5M in Seed Funding Round | GenomeWeb
• Nostos Genomics – AI-driven genetic analysis platform
• Nostos Genomics - SPEEDA Edge
• Nostos Genomics | LinkedIn
• Nostos Genomics: Funding, Team & Investors | Startup Intros
• Limbus acquires Nostos | varvis.com
• Nostos Genomics 2025 Company Profile: Valuation, Funding & Investors | PitchBook

Nostos Genomics pitch deck slides

What each slide of the Nostos Genomics pitch deck says

Slide 3

While the number of new tests and treatments is flourishing, the diagnosis of genetic diseases is still a manual and labour-intensive process cost peR cENONE 1D AFFLIGATIONS FOR GENE THERAPY PRODUCT PROGRALS SUBMTTED IN 2010-2018°" STEP 1- TESTING STEP 2 - DIAGNOSIS STEP 3 - TREATMENT ‘The sharp decline in sequencing costs led to an Bottleneck: currently, only ~ 30% of patients Cambrian explosion in availabilty of treatments, increase in access to and demand for tests. receive a diagnosis when doing 2 genetic test. * worth $2428 by 2024, * i, g —— et i 19 T 3 S

Slide 5

We have automated this interpretation process with our platform AION . /l o - weom > ((Prioritizer ) Integrate into your software with our API (€] (step2) (Seer3) (Steps) €D ‘The user uploads a patient VCF The subrmitied An infial st of Decision and selec- Finalreport file to our platform, selects datajsautomatically topTOvariantswith tion oftherelevant _including confi- ralovant HPO terms, and other processed on our associated diseases varianisfromthelist dencescores &CSV patient information (65, age, sex) proprietary platform s presented onourplatiorm exportofal results N2 < Nostos Genomics S

Slide 6

In May 2021, we launched our certified platform (CE-IVD), which is already used by many large, well-known laboratories “The results match well with our manual interpretation, and the information provided is very comprehensive.” AB DIREC Nostos Genomics | really liked the U, it's a very clean display that shows all the information that is needed for variant analysis.” VARIANT AT ALARGE “The results were amazing, the datasets found exactly what we expected (and then some). Really impressive feat of you and your team.* “The performance is high, even with the more advanced variants that we have analyzed." HEAD OF “The dashboard presents the information relevant for variant interpretation in a v…

Slide 7

With our long-term strategy, we are tapping into the massively growing market for genetic testing COSTS & ACCEPTANCE DIAGNOSTIC & PREVENTIVE TESTING o There is already a wide use of diagnostic genetic testing « Preventive testing is becoming widely adopted (e.g. prenatal screening programs) « By 2027, preventive and diagnostic genetic testing will surpass $32 billion, with a compound annual growth rate of 12.5% Wiy, Nostos Genomics e Wy, S o We have seen sharp decline in sequencing costs over the recent years o The cost per genome sequenced has been reduced from $3 billion to less than $1,000 in the past 15 years = Covid pandemic has accelerated adoption of genetic testing HEALTH CARE SYSTE…

Slide 8

Our roadmap addresses the core economic needs for target customers and will build on top of a core offering over time Next 18 months > 18 months > 36 months < Nostos Genomics IS

Slide 9

Built by a mission-driven team of 15 experts in genetic data, machine learning and business building Highlights « Experienced leadership team Successfully helped scaling major digital health & ML companies. + Strong scientific track record The team has published 150+ scientific papers and has finks with top European universities « World leading advisory team We are supported by Prof. Han Bruaner (Radboud UMC) / Dr. Meartin Kircher (Charits Berlin) / Or Lea Starita (University of Waskington) / Prof. Eigar Fleisch (ETH Zurich & University of St. Gallen) Wiy, Nostos Genomics e ", QU WORLD-CLASS LEADERSHIP: David Gorgan CEO & Co-Founder Dr. Racio Acufia Hidalgo, MD, PhD ‘Experienced with medica…

Slide 11

Join us in our mission to empower people living with genetic diseases to start a new journey We can double the number of diagnoses and help the 70% of patients that currently don't receive 2 diagnosis when doing CLEAR & FAST DIAGNOSIS a genetic test. Our focus on hereditary genetic diseases enables genomic prevention. For example, allowing parents to provide the best GENOMIC level of care to their child. PREVENTION We are changing the way how genetic disease diagnoses are given and thereby making it more accessible and affordable ACCESSIBLE AND AFFORDABLE for everyone. Wi, Nostos Genomics S A

Slide text above is read directly from the Nostos Genomics deck PDF embedded on this page.

Related fundraising guides (24)

• Covey Pitch Deck Teardown: Decentralizing Asset Management via Immutable Track Records
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• FX HedgePool Pitch Deck Teardown: Disintermediating the $66 Trillion FX Swap Market
• Auki Labs Pitch Deck Teardown: A $13M Bet on Replacing GPS for the Spatial Metaverse
• Include Pitch Deck Teardown: Scaling Smart City Infrastructure Through Global Distribution
• CMR Surgical Pitch Deck Teardown: A $600M Masterclass in Ecosystem-Led Medical Robotics
• Limetree Pitch Deck Teardown: A Case Study in Early-Stage Family Media Preservation
• Evy Pitch Deck Teardown: A 10-Slide Masterclass in Embedded Insurance Minimalism
• Arist Pitch Deck Teardown: The $12M Series A Memo Strategy for Micro-Learning
• Hopscotch Pitch Deck Teardown: A $8M Seed Round for Pediatric Behavioral Health Infrastructure
• Circ Pitch Deck Teardown: Solving the Polycotton Recycling Gap with Hydrothermal Tech
• Yalo Pitch Deck Teardown: Dominating Enterprise Conversational AI via WhatsApp
• EnergyX Pitch Deck Teardown: A Masterclass in Industrial Validation and Scientific Pedigree
• Alphin Pitch Deck Teardown: A $6M Series A Masterclass in Local SMB Digitization
• HiBob Pitch Deck Teardown: A Narrative-Driven $150M Series D Masterclass
• CAMP4 Therapeutics Pitch Deck Teardown: A $100M Masterclass in Biotech Platform Validation
• Yelp Pitch Deck Teardown: A Post-IPO Growth Story Focused on Local Ad Dominance
• EcoLocked Pitch Deck Teardown: Decarbonizing Construction via Biochar Admixes
• AgBiome Pitch Deck Teardown: A $116M Series D Masterclass in Platform Validation
• Hang Pitch Deck Teardown: A $16M Series A Masterclass in Web3 Enterprise Utility
• Bloom Community Pitch Deck Teardown: Scaling Niche Social Networks Through Event Flywheels
• Sunnyside Pitch Deck Teardown: A Masterclass in Market Expansion via Habit Modification
• Dalan Animal Health Pitch Deck Teardown: A $3.5M Seed for the First Honeybee Vaccine
• 10KC Pitch Deck Teardown: A $56M Growth Round Built on Enterprise Social Proof

Decks from the same year (1)

• 2021 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $1M to $10M

Browse companies alphabetically (1)

• Pitch decks from companies starting with N

More pitch deck teardowns (16)

• Nord Security Pitch Deck Breakdown: How Brand Dominance Secured a $100M Series A
• Normalyze Pitch Deck Teardown: A Data-Centric Approach to Cloud Security
• Normative Pitch Deck Breakdown: A $31M Masterclass in Regulatory-Driven Carbon Accounting
• North American Palladium Pitch Deck Teardown: A Heavy Industry Play for Commodity Growth
• Northern Spirits Biosciences Group Pitch Deck Teardown: A Vertically Integrated R&D Play
• Northspyre Pitch Deck Breakdown: A Data-Driven Masterclass in Real Estate SaaS Efficiency
• Northspyre Pitch Deck Teardown: A Data-Driven $25 Million Series B for Real Estate OS
• Nory Pitch Deck Teardown: A Masterclass in Founder-Market Fit and Efficiency Metrics
• Notably Pitch Deck Breakdown: Selling the Future of AI-Powered Qualitative Research
• Notation Capital Fund 1 Pitch Deck Teardown: A Thesis-Driven Approach to NYC Pre-Seed
• Notation II Pitch Deck Teardown: A Masterclass in Pre-Seed Fund Thesis and Portfolio Construction
• Not Boring Capital Fund II Pitch Deck Breakdown: The Media-First Venture Model
• Not Boring Capital Fund I Pitch Deck Breakdown: The Rise of the Solo Capitalist
• Not Boring Capital Pitch Deck Breakdown: The Solo GP Media-First Thesis
• Notion Pitch Deck Breakdown: The Case for SaaS Consolidation and Unified Workspaces
• Noto Pitch Deck Breakdown: Vertical SaaS for the $11B Lesson-Based Economy

Recently published pitch deck teardowns (12)

• Direct Dairy Holding Pitch Deck Teardown: Disrupting the Milk Supply Chain with Automation
• Duco Pitch Deck Teardown: A Masterclass in Land-and-Expand Financial SaaS Metrics
• Dynamaxx Clinics SPV I LLC Pitch Deck Teardown: A $1M Regional Medical Spa Rollout
• EchoMe Pitch Deck Teardown: A Social Layer for Music Streaming Services
• E-Contenta Pitch Deck Teardown: A Brand-Centric Approach to Native Advertising
• Elite Events Pitch Deck Teardown: A Service-Based Promoter Deck Lacking Scale and Ask
• Lara Exploration Pitch Deck Teardown: The Prospect Generator Model in Mining
• PRAGATI Pitch Deck Teardown: A Conceptual Framework for Blockchain-Based P2P Lending
• Teranga Gold Pitch Deck Teardown: A Masterclass in Public Market Resource Reporting
• Unzipped Pitch Deck Teardown: A Placeholder Template Lacking Specific Financial Data
• Vajro Pitch Deck Teardown: A Case Study in Shopify Ecosystem Scalability
• POPAPP Pitch Deck Breakdown: A Visual Masterclass in Prototyping Simplicity

Fundraising library · Pitch deck examples · Investor directory · Founder database